Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scholar Rock HoldingFRA:2QK +0.39%33 Debt-to-EBITDA is -0.49 as of Jun. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 297 Biotechnology companies, Scholar Rock Holding ranks worse than 336700% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Scholar Rock Holding's Debt-to-EBITDA or its related term are showing as below:
FRA:2QK'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.67 Med: -0.28 Max: -0.01
Current: -0.51
During the past 10 years, the highest Debt-to-EBITDA Ratio of Scholar Rock Holding was -0.01. The lowest was -0.67. And the median was -0.28.
FRA:2QK's Debt-to-EBITDA is ranked worse than 100% of 297
companies
in the Biotechnology industry
Industry Median: 1.16
vs FRA:2QK: -0.51
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Scholar Rock Holding Debt-to-EBITDA Related Terms
Scholar Rock Holding Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Scholar Rock Holding's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QK vs DFTX, DNTH, ORKA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Scholar Rock Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Scholar Rock Holding (FRA:2QK) has a Debt-to-EBITDA of -0.49 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Scholar Rock Holding. According to the industry distribution chart, Scholar Rock Holding ranks #999999 out of 297 companies in the Biotechnology industry.
Is Scholar Rock Holding's Debt-to-EBITDA too high?
Scholar Rock Holding's current Debt-to-EBITDA is -0.49. Based on the distribution chart, Scholar Rock Holding ranks #999999 out of 297 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's Debt-to-EBITDA compare to DFTX and DNTH?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #999999 out of 297 companies for Debt-to-EBITDA. This places Scholar Rock Holding in the lower half of its industry. The industry median Debt-to-EBITDA is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 297 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Scholar Rock Holding. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scholar Rock Holding's current Debt-to-EBITDA is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current Debt-to-EBITDA of -0.49. The current Debt-to-EBITDA is -0.49. Scholar Rock Holding's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current Debt-to-EBITDA is -0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
33GF Score
Get the complete analysis for FRA:2QK
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
